Overview
- BioCompute’s founder, Anagha Rajesh, announced the move in mid‑June and said the company will shift operations to San Francisco to begin developing its first V1 DNA data‑storage chips.
- The startup spent two years in Bengaluru building a lab, running thousands of experiments and raising more than ₹5 crore from investors including WTF Fund, Grad Capital and 1517 Fund to reach an end‑to‑end prototype.
- Rajesh said the decision reflects differences in investor expectations, with Silicon Valley backers focusing on long‑term technical needs rather than immediate revenue requirements.
- The relocation requires winding down the Bengaluru operation, which has involved letting go of the local team and listing lab equipment and supplies for sale.
- Coverage frames BioCompute as a test case for India’s deep‑tech ecosystem because the move highlights gaps in patient capital and institutional support that could push other frontier projects abroad.